Skip to main content

DRRX

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

DRRX Price
Price Chart

Forward-looking statistics

Beta
1.39
Risk
89.97%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees80
Market cap$47.2M

Fundamentals

Enterprise value$13.4M
Revenue$1.9M
Revenue per employee—
Profit margin-264.71%
Debt to equity37.06

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.48
Dividend per share—
Revenue per share$0.06
Avg trading volume (30 day)$35K
Avg trading volume (10 day)$15K
Put-call ratio—

Macro factor sensitivity

Growth+10.9
Credit+0.4
Liquidity-5.6
Inflation+7.4
Commodities+3.4
Interest Rates-4.2

Valuation

Dividend yield0.00%
PEG Ratio-0.65
Price to sales11.15
P/E Ratio-0.65
Enterprise Value to Revenue7.24
Price to book3.88

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day—
Ex. dividend day—

News

Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates

Durect (DRRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.27 per share a year ago.

Zacks Investment Research (March 26, 2025)
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga (December 18, 2023)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free